King Tigan Approval Expected In Six Months; Bioequivalence Data Submitted

King Pharmaceuticals anticipates NDA approval of the antiemetic Tigan (trimetrioberizamide) within six months, allowing time for FDA to review recently submitted clinical data.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet